STOCK TITAN

Palatin to Report Third Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on May 17, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

CRANBURY, N.J., May 11, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2022 operating results on Tuesday, May 17, 2022, before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 17, 2022, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.

Schedule for the Operating Results Press Release, Conference Call / Audio Webcast



Q3 Fiscal Year 2022 Results Press Release                                   

5/17/2022 at 7:30 a.m. ET



Q3 Fiscal Year 2022 Conference Call-Live     

5/17/2022 at 11:00 a.m. ET

     US/Canada Dial-In Number:    

1-800-304-0389

     International Dial-In Number: 

1-313-209-5140

     Conference ID:             

1376619



Q3 Fiscal Year 2022 Conference Call-Replay      

5/17/2022-5/24/2022

     US/Canada Dial-In Number:            

1-888-203-1112

     International Dial-In Number:              

1-719-457-0820

     Replay Passcode:   

1376619



Audio Webcast Live and Replay Access                

http://www.palatin.com

The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com.

About Palatin

Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-to-report-third-quarter-fiscal-year-2022-results-teleconference-and-webcast-to-be-held-on-may-17-2022-301545065.html

SOURCE Palatin Technologies, Inc.

Palatin Technologies, Inc.

NYSE:PTN

PTN Rankings

PTN Latest News

PTN Stock Data

32.92M
15.54M
3.35%
10.72%
9.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CRANBURY

About PTN

palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy